IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
IMUNON (NASDAQ: IMNN), a clinical-stage company developing DNA-mediated immunotherapy in Phase 3, will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York.
The company will provide a pre-recorded presentation that will be available on demand starting September 5, 2025, at 7:00 a.m. ET. IMUNON's management team will conduct in-person one-on-one meetings with investors from September 8-10, 2025. The presentation webcast will remain accessible for 90 days through the company's website.
IMUNON (NASDAQ: IMNN), azienda in fase clinica che sviluppa immunoterapie mediate dal DNA e attualmente in Fase 3, parteciperà al H.C. Wainwright 27th Annual Global Investment Conference a New York.
La società pubblicherà una presentazione preregistrata disponibile on demand a partire dal 5 settembre 2025, alle 7:00 ET. Il management di IMUNON terrà incontri individuali in presenza con gli investitori dal 8 al 10 settembre 2025. Il webcast della presentazione rimarrà accessibile per 90 giorni sul sito web aziendale.
IMUNON (NASDAQ: IMNN), compañía en fase clínica que desarrolla inmunoterapia mediada por ADN y que se encuentra en Fase 3, participará en la H.C. Wainwright 27th Annual Global Investment Conference en Nueva York.
La empresa ofrecerá una presentación pregrabada que estará disponible bajo demanda desde el 5 de septiembre de 2025 a las 7:00 a.m. ET. El equipo directivo de IMUNON llevará a cabo reuniones presenciales uno a uno con inversores del 8 al 10 de septiembre de 2025. La transmisión web de la presentación permanecerá accesible durante 90 días en el sitio web de la compañía.
IMUNON (NASDAQ: IMNN), DNA 매개 면역치료제를 개발 중이며 현재 3상에 있는 임상단계 기업이 H.C. Wainwright 27th Annual Global Investment Conference에 뉴욕에서 참가합니다.
회사는 2025년 9월 5일 오전 7:00(동부시간)부터 온디맨드로 시청 가능한 사전 녹화 프레젠테이션을 제공할 예정입니다. IMUNON 경영진은 2025년 9월 8–10일에 투자자들과 대면 일대일 미팅을 진행합니다. 프레젠테이션 웹캐스트는 회사 웹사이트를 통해 90일간 계속 열람할 수 있습니다.
IMUNON (NASDAQ: IMNN), société en phase clinique développant une immunothérapie médiée par l'ADN et actuellement en phase 3, participera à la H.C. Wainwright 27th Annual Global Investment Conference à New York.
La société proposera une présentation préenregistrée disponible à la demande à partir du 5 septembre 2025 à 7h00 (ET). L'équipe de direction d'IMUNON tiendra des réunions individuelles en personne avec des investisseurs du 8 au 10 septembre 2025. Le webdiffusion de la présentation restera accessible pendant 90 jours via le site web de la société.
IMUNON (NASDAQ: IMNN), ein klinisch tätiges Unternehmen, das DNA-vermittelte Immuntherapien entwickelt und sich in Phase 3 befindet, wird an der H.C. Wainwright 27th Annual Global Investment Conference in New York teilnehmen.
Das Unternehmen stellt eine vorab aufgezeichnete Präsentation zur Verfügung, die ab dem 5. September 2025 um 7:00 Uhr ET on demand abrufbar ist. Das Management von IMUNON wird vom 8. bis 10. September 2025 persönliche Einzelgespräche mit Investoren führen. Das Präsentations-Webcast bleibt für 90 Tage auf der Unternehmenswebsite abrufbar.
- None.
- None.
LAWRENCEVILLE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that a pre-recorded presentation from the Company will be available on demand as a part of the H.C. Wainwright 27th Annual Global Investment Conference in New York. During the conference, members of IMUNON's management team will also be conducting in-person one-on-one meetings with investors September 8 - 10, 2025.
H.C. Wainwright 27th Annual Global Investment Conference
| Presentation available: | Beginning Friday, September 5, 2025, 7:00 a.m. ET |
| Format: | Pre-recorded webcast |
| Webcast: | Here |
The webcast will be available for 90 days at the link above or under the News & Investors tab of the Imunon website at www.imunon.com.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing of enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Contacts:
| Media | Investors |
| Jenna Urban | Peter Vozzo |
| CG Life | ICR Healthcare |
| 212-253-8881 | 443-213-0505 |
| jurban@cglife.com | peter.vozzo@icrhealthcare.com |
FAQ
When is IMUNON's presentation at the H.C. Wainwright Conference 2025?
Where can I watch IMUNON's H.C. Wainwright Conference presentation?
What stage is IMUNON's DNA-mediated immunotherapy in development?
When will IMUNON management meet with investors at the H.C. Wainwright Conference?
